Efficacy & Safety of Nintedanib in Patients With Progressive Fibrosing Coal Mine Dust-Induced Interstitial Lung Disease

Inclusion Criteria: * Written Informed Consent consistent with International Conference on Harmonization Tripartite Guideline for Good Clinical Practice (ICH-GCP) and local laws signed prior to entry into the study (and prior to any study procedure including shipment of pre- existing High Resolution Computer Tomography (HRCT), spirometry or other medical records to reviewer). * Male or female patients aged \>= 18 years at Visit 1. * Progressive Fibrosing Coal Mine Dust-Induced Interstitial Lung Disease (PF-CMD- ILD) based on a history of at least 5 years' work in surface or underground coal mining and presence of Progressive Massive Fibrosis (PMF) within 24 months of screening visit; or small opacity pneumoconiosis plus decline in percent predicted FVC of \> 5% relative to high quality spirometry performed 12-24 months prior to screening visit, as assessed by the investigator. * Pneumoconiotic changes documented on screening chest HRCT. Must include large opacities consistent with PMF or small opacities consistent with pneumoconiosis (as described previously). * Carbon Monoxide Diffusion Capacity (DLCO) corrected for Hemoglobin (Hb) ≥ 30% and \<80% predicted of normal at screening visit. * FVC \>= 45% predicted at screening visit. Exclusion Criteria: * For those with PMF and past spirometry data, stable lung function based on a fall in percent predicted FVC of \< 5% relative to most recent high quality spirometry obtained at least 12 months but no more than 5 years prior t…